Chemokine Therapeutics Receives Approval From Health Canada to Commence Phase II Study in Liver Cancer

07-Mar-2008

Chemokine Therapeutics Corp. announced that it has received a No Objection Letter from Health Canada allowing the Company to begin a Phase II study in liver cancer with its lead drug candidate, CTCE-9908. The Company also recently received FDA approval for the study.

The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 123 patients. The primary end point will be to determine the response rate of tumours in patients with liver cancer treated with CTCE-9908 following transarterial chemoembolization (TACE) (a therapy used for non-resectable liver cancer) compared with patients receiving TACE alone. The Company will follow patients to also determine progression free survival, overall survival, as well as various tumour and angiogenic factors.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...